aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Echo Therapeutics, founded with the mission to revolutionize diabetes care, focuses on developing non-invasive glucose monitoring solutions. Their flagship product, the Symphony tCGM System, is a needle-free continuous glucose monitoring device designed to provide diabetics with a painless and convenient way to track their glucose levels. This innovative technology aims to improve the quality of life for diabetes patients by offering a more comfortable and user-friendly alternative to traditional glucose monitoring methods.
Notable figures associated with Echo Therapeutics include key medical and technological experts who have significantly contributed to the development of the Symphony tCGM System. The company has attracted investments from prominent venture capital firms and healthcare investors, underscoring the market's confidence in their technology. Echo Therapeutics has achieved several milestones, including successful clinical trials and regulatory approvals, positioning them as a promising player in the diabetes care market. Their impact lies in enhancing patient compliance and overall diabetes management through cutting-edge, non-invasive technology.
Operating Status
Inactive
Ownership Type(s)
Public
Main Product(s)
Glucose Monitoring
Technology
Analytics, Telemedicine
Tags
Healthtech
Model Types
Hardware, Medical
Revenue Type(s)
Recurring
Customer Type(s)
Consumers
Geographic Exposure
Americas
When was Echo Therapeutics founded?
Echo Therapeutics was founded in 1989.
Where is Echo Therapeutics's headquarters located?
Echo Therapeutics's headquarters is located in Franklin, MA, US.
When was Echo Therapeutics's last funding round?
Echo Therapeutics's most recent funding round was for $1.8M (USD) in February 2016.
How many employees does Echo Therapeutics have?
Echo Therapeutics has 8 employees as of Feb 5, 2024.
How much has Echo Therapeutics raised to-date?
As of July 05, 2023, Echo Therapeutics has raised a total of $44.7M (USD) since Feb 8, 2016.
Add Comparison
Total Raised to Date
$44.7M
USD
Last Update Feb 8, 2016
Last Deal Details
$1.8M
USD
Feb 8, 2016
Post Ipo Debt
Total Employees Over Time
8
As of Feb 2024
Echo Therapeutics Address
10 Forge Parkway
Franklin,
Massachusetts
02038
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts